- Home
- QS vs XENE Comparison
QS vs XENE Comparison
Compare QS & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QS
- XENE
- Stock Information
- Founded
- QS 2010
- XENE 1996
- Country
- QS United States
- XENE Canada
- Employees
- QS N/A
- XENE N/A
- Industry
- QS Auto Parts:O.E.M.
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- QS Consumer Discretionary
- XENE Health Care
- Exchange
- QS Nasdaq
- XENE Nasdaq
- Market Cap
- QS 2.2B
- XENE 2.5B
- IPO Year
- QS N/A
- XENE 2014
- Fundamental
- Price
- QS $3.99
- XENE $35.54
- Analyst Decision
- QS Sell
- XENE Strong Buy
- Analyst Count
- QS 7
- XENE 9
- Target Price
- QS $5.19
- XENE $56.22
- AVG Volume (30 Days)
- QS 8.4M
- XENE 862.0K
- Earning Date
- QS 04-23-2025
- XENE 05-12-2025
- Dividend Yield
- QS N/A
- XENE N/A
- EPS Growth
- QS N/A
- XENE N/A
- EPS
- QS N/A
- XENE N/A
- Revenue
- QS N/A
- XENE N/A
- Revenue This Year
- QS N/A
- XENE N/A
- Revenue Next Year
- QS N/A
- XENE $1,553.36
- P/E Ratio
- QS N/A
- XENE N/A
- Revenue Growth
- QS N/A
- XENE N/A
- 52 Week Low
- QS $3.40
- XENE $26.74
- 52 Week High
- QS $9.52
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- QS 49.96
- XENE 49.08
- Support Level
- QS $3.77
- XENE $37.46
- Resistance Level
- QS $4.12
- XENE $39.01
- Average True Range (ATR)
- QS 0.17
- XENE 1.68
- MACD
- QS 0.03
- XENE -0.14
- Stochastic Oscillator
- QS 55.83
- XENE 48.59
About QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.